These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8948412)

  • 1. The role of neoadjuvant androgen deprivation prior to radical prostatectomy.
    Fradet Y
    Urol Clin North Am; 1996 Nov; 23(4):575-85. PubMed ID: 8948412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary.
    Abbas F; Scardino PT
    Urol Clin North Am; 1996 Nov; 23(4):587-604. PubMed ID: 8948413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out.
    Van Poppel H
    Eur Urol; 2001; 39 Suppl 1():10-4. PubMed ID: 11114595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
    Witjes WP; Schulman CC; Debruyne FM
    Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy.
    Lee F; Siders DB; McHug TA; Solomon MH; Klamerus ML
    Anticancer Res; 1997; 17(3A):1507-10. PubMed ID: 9179187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in the treatment of prostate cancer with maximal androgen deprivation.
    McLeod DG; Moul JW
    Surg Oncol Clin N Am; 1995 Apr; 4(2):345-59. PubMed ID: 7796290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.
    Klotz LH; Goldenberg SL; Jewett M; Barkin J; Chetner M; Fradet Y; Chin J; Laplante S
    Urology; 1999 Apr; 53(4):757-63. PubMed ID: 10197852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of induction androgen deprivation prior to radical prostatectomy.
    Soloway MS; Watson R
    Eur Urol; 1996; 29 Suppl 2():114-8. PubMed ID: 8717473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of neoadjuvant androgen deprivation therapy on prostatic cancer.
    Polito M; Muzzonigro G; Minardi D; Montironi R
    Eur Urol; 1996; 30 Suppl 1():26-31; discussion 38-9. PubMed ID: 8977987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
    Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
    Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
    Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation in combination with radical prostatectomy for localized prostate cancer.
    Naito S
    Int J Urol; 2001 Jul; 8(7):S19-21. PubMed ID: 11442672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant hormonal deprivation before radical prostatectomy.
    Schulman CC; Sassine AM
    Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
    Rabbani F; Perrotti M; Bastar A; Fair WR
    J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review.
    Schulman CC
    Prostate Suppl; 1994; 5():9-14. PubMed ID: 7513532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.